$IOBT News
Last published 9mo ago
- 9mo agoIOBTIO Biotech Provides Corporate UpdateGlobeNewswireRaymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel,
- 9mo agoIOBTIO Biotech Announces Exploration of Strategic AlternativesGlobeNewswireNEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that the
- 11mo agoIOBTIO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature CommunicationsGlobeNewswireFindings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanomaFive-year analysis of median progression free survival was 25.5
- 11mo agoIOBTIO Biotech Announces Participation in Upcoming December Investor ConferencesGlobeNewswireNEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the
- 11mo agoBCAXIOBTNVSOTLC+1Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting ForGlobeNewswireAUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting Principles (GAAP) are emerging
- 12mo agoIOBTIO Biotech Reports Third Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewswireTopline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although statistical
- 12mo agoIOBTIO Biotech Announces Participation in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that
- 1y agoIOBTIO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewswirePre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted
- 1y agoIOBTNVSBCAXPFENanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in OncologyPR NewswireThe global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient...
- 1y agoIOBTIO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025GlobeNewswireCylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS)
- 1y agoGTBPLPTXIOBTCELC+1Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 BillionPR NewswireUSA News Group News Commentary – Major pharmaceutical companies are unveiling breakthrough cancer data at the European Society for Medical Oncology...
- 1y agoIOBTIO Biotech Provides Update Following Pre-BLA Meeting with FDAGlobeNewswireFDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the treatment of first-line patients with advanced melanoma
- 1y agoIOBTIO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025GlobeNewswireOral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanomaPoster presentation will share final
- 1y agoIOBTIO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoIOBTIO Biotech Announces Participation in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that
- 1y agoIOBTIO Biotech Reports Second Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewswireAnnounced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but statistical
- 1y agoONCYPRPHIOBTOLMA+1Biotech Stocks Rally as Oncology Market Targets $866B by 2034PR NewswireEquity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears...
- 1y agoIOBTIO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly MissedGlobeNewswirePatients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77
- 1y agoIOBTIO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaGlobeNewswireNEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30
- 1y agoIOBTIO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare ConferenceGlobeNewswireNEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that
- 1y agoIOBTIO Biotech Reports First Quarter 2025 Financial Results and Business HighlightsGlobeNewswirePrimary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025Data presented at recent
- 1y agoIOBTIO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025GlobeNewswireNEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one
- 1y agoIOBTIO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170GlobeNewswirePreclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech
- 1y agoIOBTIO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswire• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors•
- 1y agoIOBTIO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025GlobeNewswire– Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines – NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage
- 1y agoIOBTIO Biotech Reports 2024 Business HighlightsGlobeNewswirePreparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023
- 1y agoIOBTIO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO ConferenceGlobeNewswire• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in solid tumors NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech
- 1y agoIOBTIO Biotech to Present at the 45th Annual Cowen Health Care ConferenceGlobeNewswirePresentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a
- 1y agoIOBTIO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine CandidateGlobeNewswire– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 – NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing
- 1y agoIOBTIO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck CancerGlobeNewswire-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing
- 1y agoIOBTIO Biotech secures up to €57.5 million in debt financing from the European Investment BankGlobeNewswireFunds expected to be used to advance IO Biotech's immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in 2025Commitment is part of the European Investment Bank's strategy to
- 1y agoIOBTIO Biotech Reports Third Quarter 2024 Financial Results and Provides Business HighlightsGlobeNewswirePivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma on
- 2y agoIOBTIO Biotech Announces Participation in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win®
- 2y agoIOBTIO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 StudyGlobeNewswire-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response rate of 55%
- 2y agoIOBTIO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingGlobeNewswireNEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win®
- 2y agoIOBTIO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck CancerGlobeNewswire-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals or Added Systemic
- 2y agoIOBTIO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaGlobeNewswire- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety signals observed at
- 2y agoIOBTIO Biotech Announces Participation in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today
- 2y agoIOBTIO Biotech Reports Second Quarter 2024 Financial Results and Provides Business HighlightsGlobeNewswirePhase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with
- 2y agoIOBTIO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024GlobeNewswireNEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform,
- 2y agoIOBTIO Biotech to Present at Jefferies Global Healthcare ConferenceGlobeNewswireNEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform,
- 2y agoIOBTIO Biotech Reports First Quarter 2024 Financial Results and Provides Business HighlightsGlobeNewswireOutcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in
- 2y agoIOBTIO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireNEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today
- 2y agoIOBTIO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessGlobeNewswireNEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today
- 2y agoIOBTIO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103GlobeNewswireNEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today
- 2y agoIOBTIO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerGlobeNewswireNEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today
- 2y agoIOBTIO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireNew nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage
- 2y agoIOBTIO Biotech Announces 2023 Fourth-Quarter and Year-End ResultsGlobeNewswireCompleted enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim
- 2y agoIOBTIO Biotech to Present at 44th Annual Cowen Health Care ConferenceGlobeNewswireNEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform,
- 2y agoIOBTIO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialGlobeNewswireNEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win® platform,